Seller record · nootropicsource.com

Nootropic Source

Recorded September 2026 · Standard v1.1

Fails 4 of 8 criteria. S1, prescriber requirement: No clinician evaluation is claimed anywhere on the pages read, and the only purchase condition stated is a minimum age of eighteen. 3 more criteria also fail; see the table below.

Research vendor. Passes 4 of 8 criteria. Recorded against Standard v1.1.

A research compound seller offering powders, solutions, sprays and peptides, including semaglutide and tirzepatide vials labeled for research use. It states that it synthesizes compounds in laboratories it holds equity in.

Operating entity The footer, the contact page, the privacy policy and the legal disclaimer were all read, and none of the four prints a legal entity name.

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	FAIL	nootropicsource.com/legal-disclaimer
S2	Prescription gating	FAIL	nootropicsource.com/checkout
S3	Pharmacy identification	FAIL	nootropicsource.com/shop/peptides/semaglutide
S4	Compounding disclosure	PASS	nootropicsource.com/shop/peptides/semaglutide
S5	Analytical documentation	PASS	nootropicsource.com/wp-content/uploads/Nootropic_Source-Bromantane_20180430_HPLC.jpg
S6	Business address	FAIL	nootropicsource.com/contact
S7	Price disclosure	PASS	nootropicsource.com/shop/peptides/semaglutide
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1FAILNo clinician evaluation is claimed anywhere on the pages read, and the only purchase condition stated is a minimum age of eighteen.Source: nootropicsource.com/legal-disclaimer.

S2FAILThe order path was walked from the semaglutide page at 90.00 dollars and reached a guest checkout with payment selection and no eligibility step.Source: nootropicsource.com/checkout.

S3FAILNo pharmacy is named on any of the 185 product pages or the policy pages read, and every product carries research use only labeling.Source: nootropicsource.com/shop/peptides/semaglutide.

S4PASSThe seller offers no compounded drug, and the product page carries research use only labeling above the description.Source: nootropicsource.com/shop/peptides/semaglutide.

S5PASSThree chromatograms are published as public product images, the newest dated 2019, reporting a 99.5343 percent assay on bromantane; neither GLP-1 product carries one.Source: nootropicsource.com/wp-content/uploads/Nootropic_Source-Bromantane_20180430_HPLC.jpg.

S6FAILThe footer, contact, privacy and legal pages were read across 185 product pages and none prints a street address as text; an address appears only inside a product-gallery image on the seller's own letterhead.Source: nootropicsource.com/contact.

S7PASSThe semaglutide page prints 90.00 dollars for one 3 mg vial, with quantity tiers falling to 70.00 dollars, and no account is required to see it.Source: nootropicsource.com/shop/peptides/semaglutide.

S8PASSNo letter names the entity in the FDA index, and no action has halted the business; control letter found in the same run.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: research peptides including semaglutide and tirzepatide, SARMs, nootropic powders and solutions, sprays, mushroom extracts, capsules.

Sellers passing S1, prescriber requirement

Records dated August 2026

Records dated September 2026

This seller fails criteria a medical service must meet. The records above belong to sellers that pass S1; some are partner links, disclosed on their records.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.